June 13, 2025

Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC

Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy before surgery alone in patients with resectable non–small cell lung cancer ...

The ASCO Post

June 13, 2025

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care tre...

The ASCO Post

June 13, 2025

Navigational Bronchoscopy vs Transthoracic Needle Biopsy for Lung Nodules: Diagnostic Accuracy

In a study (VERITAS) reported in The New England Journal of Medicine, Lentz et al evaluated whether the diagnostic accuracy of navigational bronchoscopy was noninferior to that of transthoracic needle...

The ASCO Post

June 10, 2025

How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO

At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to ...

The ASCO Post

June 03, 2025

How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO

At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to ...

The ASCO Post

May 23, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

March 06, 2025

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

Based on a systematic review and meta-analysis, plasma circulating tumor DNA (ctDNA) kinetics was found to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCL...

The ASCO Post

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

February 08, 2023

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been as...

The ASCO Post